3D Tumor Models
Predict efficacy and MOA in 45 days
3D tumor models are in vitro / ex vivo mimics of human tumor biology that aim to reduce and eventually replace animal tumor models in predicting efficacy and MOA outcomes in an accelerated timeline for the next generation of targeted and immunotherapies.
Complex in vitro models come in many flavors - 3D spheroids, organoids, ex vivo fragments, extracellular matrix domes, engineered hydrogels, co-culture, tri-culture, and microfluidics. We at Cypre believe the ideal model combines:
(a) the complexity of human tumor microenvironment (TME) biology, including fibroblasts, immune cells, and ECM density
(b) the predictivity of a wide range of therapeutic classes (e.g. chemotherapy, targeted therapy, immunotherapy)
(c) the throughput for comprehensive and standardized analytics such as high content imaging, cytokines and flow cytometry.
To this end, we are proud to share with you the Cypre 3D tumor model platform.
Modeled by Cypre™
Cypre 3D Tumor Models display translationally relevant TME signatures
Tumor cells orchestrate a complex, physiologically relevant response when combined with fibroblasts and PBMCs. Key cytokines are upregulated such as SDF-1 alpha, MCP-1, IL6, and TNF-alpha, to name a few. And the propogation of 3D models in our hydrogel enable long term durability of immune phenotypes such as CD3, CD4 (T helper cells), CD8 (cytotoxic T cells), CD56 (NK cells), CD163 (M2 Macrophages), and CD19 (B cells).
Standardized, High throughput Screening Process
Schematic of our streamlined workflow for 3D model setup and execution. Patient-derived xenograft (PDX) cells from Charles River are mouse-depleted and expanded in vitro prior to their incorporation into our proprietary hydrogel, VersaGel®, along with human fibroblasts and PBMCs. Compounds are dosed in a 6-dose, serially diluted format in 96-well plates. Efficacy readouts include tumor killing and growth delay via high content image analysis and MOA analytics such as T cell infiltration, cytokines, and immune phenotyping.
Genomically-Annotated PDX Tumors
Cypre partnered with Charles River Labs to leverage their PDX models listed here for Cypre 3D tumor models. Parental PDX and PDX-derived cell lines have been genomically characterized for RNAseq and WES expression.
Don’t see what you’re looking for? We are continuing to expand our model database, and would love your feedack!
Cypre 3D Tumor Model Panels
Pre-configured panels include five to 42 models of pre-validated 3D PDX tumor models, screened on a monthly cadence for efficacy and MOA.
Panel Process:
(1) Select Panel:
42 Model Panel (across solid tumor indications)
30 Model Panel (across solid tumor indications)
5 Model Panel (One indication - choose between CRC, NSCLC, RCC, melanoma, gastric, or pancreatic)
(2) Choose Analytics:
Efficacy + MOA (Tumor growth reduction and killing; immune infiltration, cytokines, immune phenotyping)
Efficacy Only (Tumor growth reduction and killing)
(3) Choose Timeline:
SOWs due by the 15th of every month, Compounds by the 25th
Data returned in 45 days for Efficacy + MOA, and 30 days for Efficacy Only
Custom Panels
For clients wishing to pick and choose your models from the above list, we offer custom panels.
Custom Process:
(1) Select Models:
Based on indication or gene expression
(2) Choose Analytics:
Efficacy + MOA (Tumor growth reduction and killing; immune infiltration, cytokines, immune phenotyping)
Efficacy Only (Tumor growth reduction and killing)
(3) Secure place in queue:
Sign SOW on an ad hoc basis
8-12 weeks execution timeline guarantee
Representative efficacy heat maps for a compound screened on the Cypre 42 Panel.
Representative compound dose response for T cell activation in a Cypre 3D tumor model.